Controlling coagulation dysregulation in xenotransplantation

Current Opinion in Organ Transplantation

Volumn 16, Issue 2, 2011, Pages 214-221

  Cowan, Peter J ^a,b   Robson, Simon C ^c   D'Apice, Anthony Jf ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

coagulation; inflammation; thrombosis; xenograft

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BLOOD CLOTTING FACTOR 10A; CD39 ANTIGEN; HEPARIN; PRAVASTATIN; THROMBOMODULIN; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLEEDING; BLOOD CLOTTING; DISSEMINATED INTRAVASCULAR CLOTTING; DNA MODIFICATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; HEART GRAFT; INFLAMMATION; INNATE IMMUNITY; KIDNEY GRAFT; LIVER CELL; LIVER GRAFT; MONOCYTE; NONHUMAN; PRIMATE; PROTEIN EXPRESSION; SWINE; THROMBOCYTE; THROMBOCYTOPENIA; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; GALACTOSYLTRANSFERASES; GENE DELETION; GRAFT REJECTION; HUMANS; IMMUNITY, INNATE; SWINE; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, HETEROLOGOUS;

EID: 79954583625     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283446c65     Document Type: Article

References (81)

1. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451:914-918.
2. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med 2008; 359:938-949.
3. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208:327-339. (Pubitemid 43210519)
4. Ndonwi M, Tuley EA, Broze GJ Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116:1344-1351.
5. Rau JC, Beaulieu LM, Huntington JA, Church FC. Serpins in thrombosis, hemostasis and fibrinolysis. J Thromb Haemost 2007; 5 (Suppl. 1):102-115. (Pubitemid 46958823)
6. Dahlback B, Villoutreix BO. The anticoagulant protein C pathway. FEBS Lett 2005; 579:3310-3316. (Pubitemid 40804679)
7. Taylor FB Jr, Peer GT, Lockhart MS, et al. Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97:1685-1688. (Pubitemid 32217234)
8. Danese S, Vetrano S, Zhang L, et al. The protein C pathway in tissue inflammation and injury: pathogenic role and therapeutic implications. Blood 2010; 115:1121-1130.
9. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785-797.
10. Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood 2009; 114:2367-2374.
11. Clark A, Weymann A, Hartman E, et al. Evidence for nontraditional activation of complement factor C3 during murine liver regeneration. Mol Immunol 2008; 45:3125-3132.
12. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682-687. (Pubitemid 43865238)
13. Ritis K, Doumas M, Mastellos D, et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006; 177:4794-4802. (Pubitemid 44469814)
14. Muller F, Mutch NJ, Schenk WA, et al. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 2009; 139:1143-1156.
15. Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and posttranscriptional mechanisms. Blood 1991; 77:542-550.
16. Navarro A, Frevel M, Gamero AM, et al. Thrombomodulin RNA is destabilized through its 30-untranslated element in cells exposed to IFN-gamma. J Interferon Cytokine Res 2003; 23:723-728. (Pubitemid 38041443)
17. Takano S, Kimura S, Ohdama S, Aoki N. Plasma thrombomodulin in health and diseases. Blood 1990; 76:2024-2029.
18. Villegas-Mendez A, Montes R, Ambrose LR, et al. Proteolysis of the endothelial cell protein C receptor by neutrophil proteinase 3. J Thromb Haemost 2007; 5:980-988. (Pubitemid 46691727)
19. Menschikowski M, Hagelgans A, Eisenhofer G, Siegert G. Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. Exp Cell Res 2009; 315:2673-2682.
20. Massberg S, Grahl L, von Bruehl ML, et al. Reciprocal coupling of coagulation and innate immunity via neutrophil serine proteases. Nat Med 2010; 16:887-896.
21. Aird WC. Endothelium and allotransplantation. Transplantation 2006; 82 (1 Suppl.):S6-S8. (Pubitemid 44035977)
22. Noris M, Remuzzi G. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10:1517-1523.
23. Bennet W, Sundberg B, Lundgren T, et al. Damage to porcine islets of Langerhans after exposure to human blood in vitro, or after intraportal transplantation to cynomolgus monkeys: protective effects of sCR1 and heparin. Transplantation 2000; 69:711-719. (Pubitemid 30174086)
24. Johansson H, Lukinius A, Moberg L, et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54:1755-1762. (Pubitemid 40770765)
25. Baumann BC, Stussi G, Huggel K, et al. Reactivity of human natural antibodies to endothelial cells from Galalpha(1,3)Gal-deficient pigs. Transplantation 2007; 83:193-201. (Pubitemid 46185210)
26. Lin CC, Ezzelarab M, Hara H, et al. Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by antinonGal IgG binding to porcine aortic endothelial cells. J Thromb Haemost 2010; 8:2001-2010.
27. Dahlback B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 2008; 112:19-27.
28. Xu J, Zhang X, Pelayo R, et al. Extracellular histones are major mediators of death in sepsis. Nat Med 2009; 15:1318-1321.
29. Siegel JB, Grey ST, Lesnikoski BA, et al. Xenogeneic endothelial cells activate human prothrombin. Transplantation 1997; 64:888-896. (Pubitemid 27422273)
30. Lawson JH, Daniels LJ, Platt JL. The evaluation of thrombomodulin activity in porcine to human xenotransplantation. Transplant Proc 1997; 29:884-885. (Pubitemid 27126004)
31. Roussel JC, Moran CJ, Salvaris EJ, et al. Pig thrombomodulin binds human thrombin but is a poor cofactor for activation of human protein C and TAFI. Am J Transplant 2008; 8:1101-1112. (Pubitemid 351766700)
32. Miwa Y, Yamamoto K, Onishi A, et al. Potential value of human thrombomodulin and DAF expression for coagulation control in pig-to-human xenotransplantation. Xenotransplantation 2010; 17:26-37.
33. Schulte Am Esch J, 2nd, Robson SC, Knoefel WT, et al. O-linked glycosylation and functional incompatibility of porcine vonWillebrand factor for human platelet GPIb receptors. Xenotransplantation 2005; 12:30-37. (Pubitemid 40105146)
34. Kopp CW, Siegel JB, Hancock WW, et al. Effect of porcine endothelial tissue factor pathway inhibitor on human coagulation factors. Transplantation 1997; 63:749-758. (Pubitemid 27132211)
35. Kopp CW, Robson SC, Siegel JB, et al. Regulation of monocyte tissue factor activity by allogeneic and xenogeneic endothelial cells. Thromb Haemost 1998; 79:529-538. (Pubitemid 28120785)
36. Lee KF, Salvaris EJ, Roussel JC, et al. Recombinant pig TFPI efficiently regulates human tissue factor pathways. Xenotransplantation 2008; 15:191-197. (Pubitemid 352000255)
37. Lin CC, Chen D, McVey JH, et al. Expression of tissue factor and initiation of clotting by human platelets and monocytes after incubation with porcine endothelial cells. Transplantation 2008; 86:702-709.
38. Ghanekar A, Mendicino M, Liu H, et al. Endothelial induction of fgl2 contributes to thrombosis during acute vascular xenograft rejection. J Immunol 2004; 172:5693-5701. (Pubitemid 38542073)
39. Spiezia L, Bertini D, Boldrin M, et al. Reference values for thromboelastometry (ROTEM(R)) in cynomolgus monkeys (Macaca fascicularis). Thromb Res 2010; 126:e294-e297.
40. Lin CC, Cooper DK, Dorling A. Coagulation dysregulation as a barrier to xenotransplantation in the primate. Transpl Immunol 2009; 21:75-80.
41. Cowan PJ, d'Apice AJ. Complement activation and coagulation in xenotransplantation. Immunol Cell Biol 2009; 87:203-208.
42. Pierson RN 3rd, Dorling A, Ayares D, et al. Current status of xenotransplantation and prospects for clinical application. Xenotransplantation 2009; 16:263-280.
43. Ekser B, Cooper DK. Overcoming the barriers to xenotransplantation: prospects for the future. Expert Rev Clin Immunol 2010; 6:219-230.
44. Schmelzle M, Schulte Esch J 2nd, Robson SC. Coagulation, platelet activation and thrombosis in xenotransplantation. Curr Opin Organ Transplant 2010; 15:212-218.
45. Ezzelarab M, Garcia B, Azimzadeh A, et al. The innate immune response and activation of coagulation in alpha1,3-galactosyltransferase gene-knockout xenograft recipients. Transplantation 2009; 87:805-812.
46. Lin CC, Ezzelarab M, Shapiro R, et al. Recipient tissue factor expression is associated with consumptive coagulopathy in pig-to-primate kidney xenotransplantation. Am J Transplant 2010; 10:1556-1568.
47. Griesemer AD, Hirakata A, Shimizu A, et al. Results of gal-knockout porcine thymokidney xenografts. Am J Transplant 2009; 9:2669-2678.
48. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008; 172:1471-1481. (Pubitemid 351793341)
49. Bauer A, Postrach J, Thormann M, et al. First experience with heterotopic thoracic pig-to-baboon cardiac xenotransplantation. Xenotransplantation 2010; 17:243-249.
50. Knosalla C, Yazawa K, Behdad A, et al. Renal and cardiac endothelial heterogeneity impact acute vascular rejection in pig-to-baboon xenotransplantation. Am J Transplant 2009; 9:1006-1016.
51. Ekser B, Long C, Echeverri GJ, et al. Impact of thrombocytopenia on survival of baboons with genetically modified pig liver transplants: clinical relevance. Am J Transplant 2010; 10:273-285.
52. Burlak C, Paris LL, Chihara RK, et al. The fate of human platelets perfused through the pig liver: implications for xenotransplantation. Xenotransplantation 2010; 17:350-361.
53. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709. (Pubitemid 32204987)
54. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34:17-60.
55. LaRosa SP, Opal SM. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005; 21:433-448. (Pubitemid 40898153)
56. Ramackers W, Friedrich L, Tiede A, et al. Effects of pharmacological intervention on coagulopathy and organ function in xenoperfused kidneys. Xenotransplantation 2008; 15:46-55. (Pubitemid 351360241)
57. Feistritzer C, Schuepbach RA, Mosnier LO, et al. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 2006; 281:20077-20084. (Pubitemid 44065782)
58. Iba T, Nakarai E, Takayama T, et al. Combination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis model. Crit Care 2009; 13:R203.
59. Nagato M, Okamoto K, Abe Y, et al. Recombinant human soluble thrombomodulin decreases the plasma high-mobility group box-1 protein levels, whereas improving the acute liver injury and survival rates in experimental endotoxemia. Crit Care Med 2009; 37:2181-2186.
60. Sharfuddin AA, Sandoval RM, Berg DT, et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009; 20:524-534.
61. Cui W, Wilson JT, Wen J, et al. Thrombomodulin improves early outcomes after intraportal islet transplantation. Am J Transplant 2009; 9:1308-1316.
62. Seshan SV, Franzke CW, Redecha P, et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid antibodies. Blood 2009; 114:1675-1683.
63. Goto M, Johansson H, Maeda A, et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 2004; 77:741-747. (Pubitemid 38366981)
64. Van der Windt DJ, Bottino R, Casu A, et al. Long-term controlled normoglycemia in diabetic nonhuman primates after transplantation with hCD46 transgenic porcine islets. Am J Transplant 2009; 9:2716-2726.
65. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007; 56:2008-2015. (Pubitemid 47195827)
66. Cui H, Tucker-Burden C, Cauffiel SM, et al. Long-term metabolic control of autoimmune diabetes in spontaneously diabetic nonobese diabetic mice by nonvascularized microencapsulated adult porcine islets. Transplantation 2009; 88:160-169.
67. Dufrane D, Gianello P. Pig islets for clinical islet xenotransplantation. Curr Opin Nephrol Hypertens 2009; 18:495-500.
68. Berman DM, O'Neil JJ, Coffey LC, et al. Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold. Am J Transplant 2009; 9:91-104.
69. Van der Windt DJ, Echeverri GJ, Ijzermans JN, Cooper DK. The choice of anatomical site for islet transplantation. Cell Transplant 2008; 17:1005-1014.
70. Echeverri GJ, McGrath K, Bottino R, et al. Endoscopic gastric submucosal transplantation of islets (ENDO-STI): technique and initial results in diabetic pigs. Am J Transplant 2009; 9:2485-2496.
71. Conway EM, Van de Wouwer M, Pollefeyt S, et al. The lectin-like domain of thrombomodulin confers protection from neutrophil-mediated tissue damage by suppressing adhesion molecule expression via nuclear factor kappa B and mitogen-activated protein kinase pathways. J Exp Med 2002; 196:565-577. (Pubitemid 35024436)
72. Van de Wouwer M, Plaisance S, De Vriese A, et al. The lectin-like domain of thrombomodulin interferes with complement activation and protects against arthritis. J Thromb Haemost 2006; 4:1813-1824. (Pubitemid 44144810)
73. Kopp CW, Grey ST, Siegel JB, et al. Expression of human thrombomodulin cofactor activity in porcine endothelial cells. Transplantation 1998; 66:244-251. (Pubitemid 28370009)
74. Crikis S, Zhang XM, Dezfouli S, et al. Anti-inflammatory and anticoagulant effects of transgenic expression of human thrombomodulin in mice. Am J Transplant 2010; 10:242-250.
75. Aigner B, Klymiuk N, Wolf E. Transgenic pigs for xenotransplantation: selection of promoter sequences for reliable transgene expression. Curr Opin Organ Transplant 2010; 15:201-206.
76. Kaczmarek E, Koziak K, Sevigny J, et al. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem 1996; 271:33116-33122. (Pubitemid 27008752)
77. Dwyer KM,Robson SC,Nandurkar HH, et al. Thromboregulatory manifestations in humanCD39transgenic mice and the implications for thrombotic disease and transplantation. J Clin Invest 2004; 113:1440-1446.
78. Dwyer KM, Mysore TB, Crikis S, et al. The transgenic expression of human CD39 on murine islets inhibits clotting of human blood. Transplantation 2006; 82:428-432. (Pubitemid 44223045)
79. Crikis S, Lu B, Murray-Segal LM, et al. Transgenic overexpression of CD39 protects against renal ischemia-reperfusion and transplant vascular injury. Am J Transplant 2010; 10:2586-2595.
80. Chen D, Weber M, McVey JH, et al. Complete inhibition of acute humoral rejection using regulated expression of membrane-tethered anticoagulants on xenograft endothelium. Am J Transplant 2004; 4:1958-1963. (Pubitemid 39611622)
81. Lee H, Lee B, Kim Y, et al. Characterization of transgenic pigs that express human decay accelerating factor and cell membrane-tethered human tissue factor pathway inhibitor. Reprod Domest Anim 2010; DOI: 10.1111/j.1439-0531. 2010.01670.x.